Skip to main content

CORRECTION article

Front. Oncol., 02 December 2024
Sec. Cancer Immunity and Immunotherapy
Volume 14 - 2024 | https://doi.org/10.3389/fonc.2024.1516024
This article is part of the Research Topic Integrating Molecular Mechanisms, Immunotherapy, and Drug Sensitivity in Cancer Immunology and Oncology View all 7 articles

Corrigendum: Case report: A sustained survival benefit of third-line immunotherapy for refractory thymic carcinoma

This article is a correction to:

  1. Case report: A sustained survival benefit of third-line immunotherapy for refractory thymic carcinoma

    1. Read original article
Mi Meng&#x;Mi Meng1†Bo Yu&#x;Bo Yu2†Jie LuoJie Luo3Yuju BaiYuju Bai1Lin LiLin Li1Shicheng ChenShicheng Chen2Sisi He*Sisi He1*Hu Ma*Hu Ma1*
  • 1Department of Thoracic Oncology, The second Affiliated Hospital of Zunyi Medical University, Zunyi, China
  • 2Department of Urology, The second Affiliated Hospital of Zunyi Medical University, Zunyi, China
  • 3Department of Radiation Oncology, Guiqian International General Hospital, Guiyang, China

A Corrrigendum on
Case report: A sustained survival benefit of third-line immunotherapy for refractory thymic carcinoma

By Meng M, Yu B, Luo J, Bai Y, Li L, Chen S, He S and Ma H (2024). Front. Oncol. 14:1326006. doi: 10.3389/fonc.2024.1326006

In the published article, there was an error in affiliation 1. Instead of “Department of Thoracic Oncology, Affiliated Hospital of Zunyi Medical College, Zunyi, China”, it should be “Department of Thoracic Oncology, The second Affiliated Hospital of Zunyi Medical University, Zunyi, China”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: sintilimab, thymic carcinoma(TC), therapeutic option, case report, anti-PD-1

Citation: Meng M, Yu B, Luo J, Bai Y, Li L, Chen S, He S and Ma H (2024) Corrigendum: Case report: A sustained survival benefit of third-line immunotherapy for refractory thymic carcinoma. Front. Oncol. 14:1516024. doi: 10.3389/fonc.2024.1516024

Received: 23 October 2024; Accepted: 25 November 2024;
Published: 02 December 2024.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2024 Meng, Yu, Luo, Bai, Li, Chen, He and Ma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Hu Ma, bWFodWFiQDE2My5jb20=; Sisi He, c2lzaWhlMTIxOUAxNjMuY29t

†These authors have contributed equally to this work and share first authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.